Get the Stockscreener App
55.62
1.37%
0.75
Pre-market:
57.00
1.38
+2.48%
Overview
News
Price History
Option Chain
Why NVO Down?
Discussions
Forecast
Stock Split
Dividend History
Novo Nordisk Adr stock is traded at $55.62, with a volume of 13.49M.
It is up +1.37% in the last 24 hours and up +6.12% over the past month.
With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.
See More
Previous Close:
$54.87
Open:
$56.5
24h Volume:
13.49M
Relative Volume:
0.87
Market Cap:
$188.56B
Revenue:
$45.44B
Net Income/Loss:
$16.18B
P/E Ratio:
15.31
EPS:
3.634
Net Cash Flow:
$9.21B
1W Performance:
+2.47%
1M Performance:
+6.12%
6M Performance:
-27.91%
1Y Performance:
-59.40%
1-Day Range:
$55.55
$56.98
1-Week Range:
$52.72
$56.98
52-Week Range:
$45.05
$138.22
Novo Nordisk Adr Stock (NVO) Company Profile
Name
Novo Nordisk Adr
Sector
Industry
Phone
-
Address
-
Compare NVO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NVO
Novo Nordisk Adr
|
55.62 | 243.81B | 45.44B | 16.18B | 9.21B | 3.634 |
|
LLY
Lilly Eli Co
|
748.19 | 677.17B | 53.26B | 13.80B | -50.20M | 15.30 |
|
JNJ
Johnson Johnson
|
177.40 | 428.83B | 90.62B | 22.66B | 18.18B | 9.35 |
|
ABBV
Abbvie Inc
|
217.61 | 385.71B | 58.33B | 3.73B | 18.24B | 2.10 |
|
NVS
Novartis Ag Adr
|
123.31 | 240.28B | 53.40B | 13.68B | 16.89B | 6.9231 |
|
MRK
Merck Co Inc
|
81.02 | 206.84B | 63.43B | 16.42B | 14.72B | 6.49 |
Novo Nordisk Adr Stock (NVO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-09-25 | Upgrade | Bernstein | Mkt Perform → Outperform |
| Aug-13-25 | Upgrade | BNP Paribas Exane | Underperform → Neutral |
| Aug-05-25 | Downgrade | UBS | Buy → Neutral |
| Jul-31-25 | Downgrade | HSBC Securities | Buy → Hold |
| Jul-30-25 | Downgrade | Barclays | Overweight → Equal Weight |
| Apr-17-25 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Mar-13-25 | Upgrade | Kepler | Hold → Buy |
| Mar-03-25 | Downgrade | Stifel | Buy → Hold |
| Feb-12-25 | Initiated | Morgan Stanley | Equal-Weight |
| Jan-06-25 | Upgrade | Bernstein | Underperform → Mkt Perform |
| May-30-24 | Initiated | Goldman | Buy |
| Apr-12-24 | Initiated | BMO Capital Markets | Outperform |
| Jan-23-24 | Initiated | Morgan Stanley | Overweight |
| Jan-16-24 | Resumed | UBS | Neutral |
| Dec-01-23 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-02-23 | Initiated | Argus | Buy |
| Jul-14-23 | Initiated | HSBC Securities | Buy |
| Jul-15-22 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jun-28-22 | Downgrade | UBS | Neutral → Sell |
| Jun-27-22 | Upgrade | Exane BNP Paribas | Underperform → Neutral |
| Jun-07-22 | Upgrade | JP Morgan | Neutral → Overweight |
| May-31-22 | Upgrade | Guggenheim | Neutral → Buy |
| Apr-25-22 | Upgrade | Cowen | Market Perform → Outperform |
| Apr-12-22 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Mar-16-22 | Upgrade | Deutsche Bank | Hold → Buy |
| Jan-25-22 | Downgrade | Liberum | Hold → Sell |
| Dec-20-21 | Downgrade | JP Morgan | Overweight → Neutral |
| Dec-17-21 | Downgrade | Deutsche Bank | Buy → Hold |
| Jan-20-21 | Downgrade | Credit Suisse | Outperform → Neutral |
| Jan-15-21 | Initiated | Deutsche Bank | Buy |
| Sep-29-20 | Initiated | Berenberg | Hold |
| Jul-06-20 | Downgrade | BofA Securities | Buy → Neutral |
| May-11-20 | Downgrade | UBS | Buy → Neutral |
| May-04-20 | Initiated | Cowen | Market Perform |
| Mar-16-20 | Upgrade | BofA/Merrill | Neutral → Buy |
| Jan-03-20 | Downgrade | Guggenheim | Buy → Neutral |
| Nov-18-19 | Upgrade | Barclays | Equal Weight → Overweight |
| Sep-17-19 | Upgrade | Citigroup | Neutral → Buy |
| Aug-30-19 | Downgrade | Jefferies | Hold → Underperform |
| Jun-20-19 | Downgrade | Deutsche Bank | Buy → Hold |
| Jun-11-19 | Upgrade | Barclays | Underweight → Equal Weight |
| Apr-29-19 | Upgrade | Credit Suisse | Neutral → Outperform |
| Jan-29-19 | Initiated | Exane BNP Paribas | Outperform |
| Dec-11-18 | Resumed | Jefferies | Hold |
| Oct-09-18 | Initiated | Guggenheim | Buy |
| Dec-29-17 | Upgrade | JP Morgan | Underweight → Neutral |
| Dec-06-17 | Upgrade | BofA/Merrill | Neutral → Buy |
| Dec-01-17 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Sep-25-17 | Downgrade | Exane BNP Paribas | Outperform → Neutral |
| Sep-06-17 | Upgrade | BofA/Merrill | Underperform → Neutral |
View All
Novo Nordisk Adr Stock (NVO) Latest News
Here Is My Top Stock Pick Among the Weight Loss Industry Leaders - The Motley Fool
ROSEN, NATIONAL INVESTOR RIGHTS COUNSEL, Encourages Novo Nordisk A/S Investors to Secure Counsel Before Important Deadline in Securities Class Action - GlobeNewswire Inc.
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Novo Nordisk A/S of Class Action Lawsuit and Upcoming DeadlinesNVO - cnhinews.com
Is the Market Bullish or Bearish on Novo Nordisk? - Sahm
Faruqi & Faruqi Reminds Novo Nordisk Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of September 30, 2025 - GlobeNewswire Inc.
Emmy Award Success for Passion and Robert Valleys 400 Boys Episode in Netflixs Love, Death and Robots - DLH.net
Teva Pharmaceutical ADR Trying To Close In On Key Technical Measure - Investor's Business Daily
NOVO_B Stock Price and Chart — OMXCOP:NOVO_B - TradingView
ROSEN, HIGHLY RANKED INVESTOR COUNSEL, Encourages Novo Nordisk A/S Investors to Secure Counsel Before Important Deadline in Securities Class Action - GlobeNewswire Inc.
ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Novo Nordisk A/S Investors to Secure Counsel Before Important Deadline in Securities Class Action - GlobeNewswire Inc.
Novo Nordisk Slumps While Philips Shines In European ADRs - Finimize
NVO’s Debt-to-Equity Ratio at 0.59: What It Means for Novo Nordisk ADR’s Future - investchronicle.com
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Hims & Hers Health, Inc. of Class Action Lawsuit and Upcoming Deadlines - GlobeNewswire Inc.
Hims & Hers (HIMS) Stock Lawsuits: Investors Urged to Act - GlobeNewswire Inc.
Novo Nordisk A/S Class Action Lawsuit: Pomerantz Law Firm Reminds Investors of Upcoming Deadlines - AInvest
HIMS & HERS HEALTH SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuits Against Hims & Hers Health, Inc. - GlobeNewswire Inc.
INVESTOR DEADLINE NEXT WEEK: Robbins Geller Rudman & Dowd LLP Announces that Hims & Hers Health, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - GlobeNewswire Inc.
Using data models to predict Novo Nordisk A s (b Shares) Adrhedged stock movementBuy Signal & Weekly Stock Performance Updates - Newser
Reversal indicators forming on Novo Nordisk A s (b Shares) Adrhedged stockJuly 2025 Action & Daily Growth Stock Investment Tips - Newser
Can momentum traders help lift Novo Nordisk A s (b Shares) Adrhedged2025 Stock Rankings & Long-Term Safe Investment Plans - Newser
Is Novo Nordisk A s (b Shares) Adrhedged showing signs of accumulationJuly 2025 Institutional & Low Risk Entry Point Tips - Newser
Is Novo Nordisk A s (b Shares) Adrhedged still worth holding after the dipTrade Risk Assessment & Consistent Growth Equity Picks - Newser
Does Novo Nordisk A s (b Shares) Adrhedged fit your quant trading modelMarket Trend Summary & Detailed Earnings Play Alerts - Newser
Is Novo Nordisk A s (b Shares) Adrhedged stock ready for a breakoutMarket Risk Report & Verified Short-Term Plans - Newser
What moving averages say about Novo Nordisk A s (b Shares) Adrhedged2025 Top Gainers & Community Verified Swing Trade Signals - Newser
What’s next for Novo Nordisk A s (b Shares) Adrhedged stock priceEarnings Recap Report & Expert Approved Momentum Trade Ideas - Newser
Earnings visualization tools for Novo Nordisk A s (b Shares) AdrhedgedChart Signals & Precise Entry and Exit Recommendations - Newser
Using portfolio simulators with Novo Nordisk A s (b Shares) Adrhedged includedJuly 2025 Catalysts & Verified Momentum Stock Ideas - Newser
Novo Nordisk Adr Stock (NVO) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.16%
0.42%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):